Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Estimates Preliminary Q2 Revenues of $1.7M to $1.8M

NEW YORK (GenomeWeb News) — Cancer Genetics today said in a regulatory document that its second-quarter revenues are expected to be in the range of $1.7 million and $1.8 million.

That compares to $1.1 million in the second quarter of 2012.

Figures for the three monthes ended June 30, 2013 include no grant revenues, compared to $184,500 a year ago. Revenue increase for the recently completed period "substantially" resulted from increased revenues from a clinical trials client, the Rutheford, N.J.-firm, which went public in April, said in a document filed with the US Securities and Exchange Commission.

Preliminary gross profit for the second quarter is estimated at between $520,000 and $580,000, it added, while preliminary operating loss is anticipated at between $1.6 million and $1.9 million. .

Cancer Genetics had about $1.9 million in cash and cash equivalents at the end of the quarter. Last month, it filed a preliminary prospectus to offer $15 million in a public offering of its stock.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.